公开(公告)号：US12233109B2

公开(公告)日：2025-02-25

申请号：US17479428

申请日：2021-09-20

Applicant: The Johns Hopkins University

Inventor： Seulki Lee ,  Ted M. Dawson ,  Han Seok Ko ,  Valina L. Dawson ,  Seung Pil Yun ,  Magdalena Scully

IPC: A61K38/26 ,  A61K9/00 ,  A61K38/38 ,  A61K47/60 ,  A61K47/68 ,  A61P25/16 ,  A61P25/28

Abstract: The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system.

公开(公告)号：US20250057979A1

公开(公告)日：2025-02-20

申请号：US18668193

申请日：2024-05-19

Applicant: University of South Florida

Inventor： Bojjibabu Chidipi

IPC: A61K48/00 ,  A61K31/055 ,  A61K31/47 ,  A61K31/566 ,  A61K38/17 ,  A61K45/06 ,  A61P9/06 ,  A61P25/28 ,  C12N15/86 ,  G01N33/543 ,  G01N33/68

Abstract: The present disclosure provides for a method of treating Friedrich's Ataxia in a subject in need thereof comprising administering to the subject a composition to upregulate type 2 ryanodine receptors (Ryr2), a composition to activate Ca2+ release, a composition to upregulate SERCA2a, a composition to upregulate Phasoplamban (PLN), a composition to upregulate Ca2+/calmodulin-dependent protein kinase II (CaMKII), or any combination thereof. Further provided herein is a method of diagnosing Friedrich's Ataxia and a kit related thereto.

公开(公告)号：US20250057793A1

公开(公告)日：2025-02-20

申请号：US18720456

申请日：2022-12-15

Applicant: The United States Government as represented by the Department of Veterans Affairs ,  Rush University Medical Center

Inventor： Kalipada Pahan

IPC: A61K31/192 ,  A61K31/045 ,  A61K31/198 ,  A61K31/216 ,  A61K31/222 ,  A61P25/00 ,  A61P25/28

Abstract: Disclosed are salts of benzoic acid and prodrugs thereof for slowing the progression of or reducing the severity of a symptom associated with a nervous system injury in a subject.

公开(公告)号：US12226441B2

公开(公告)日：2025-02-18

申请号：US18327583

申请日：2023-06-01

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： I-Hong Pan ,  Kuei-Chang Li ,  Zong-Keng Kuo ,  Chu-Hsun Lu ,  Yen-Wu Hsieh ,  Shu-Fang Wen

IPC: A61K36/074 ,  A61K31/575 ,  A61K36/185 ,  A61K36/725 ,  A61K36/77 ,  A61P1/00 ,  A61P25/20 ,  A61P25/28

Abstract: A composition for inhibiting intestinal permeability, treating leaky gut related diseases and/or preventing leaky gut related diseases including a Chinese herbal compound material or a Chinese herbal compound extract is provided. The Chinese herbal compound material includes Ganoderma, red jujube, longan and lotus seed. Moreover, the Chinese herbal compound extract includes a Ganoderma extract, a red jujube extract, a longan extract and a lotus seed extract.

公开(公告)号：US20250051781A1

公开(公告)日：2025-02-13

申请号：US18722895

申请日：2022-12-21

Applicant: Ionis Pharmaceuticals, Inc.

Inventor： Huynh-Hoa Bui ,  Bethany Fitzsimmons ,  Holly Kordasiewicz ,  Tamar R. Grossman

IPC: C12N15/113 ,  A61K31/712 ,  A61P25/28

Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of GYSI RNA in a cell or subject, and in certain instances reducing the amount of GYSI protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a glycogen storage disease. Such glycogen storage diseases include Lafora disease, adult polyglucosan body disease (APBD), Andersen's disease, and Pompe disease.

公开(公告)号：US20250049900A1

公开(公告)日：2025-02-13

申请号：US18696444

申请日：2022-09-29

Applicant: Janssen Pharmaceuticals, Inc. ,  AC Immunce SA

Inventor： Andrea Pfeifer ,  Elizabeth Anne Ramsburg

IPC: A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61P25/28 ,  A61P37/04

Abstract: Methods for inducing anti-phosphorylated Tau antibodies without inducing a serious adverse event in humans are described. The methods include administering to the subject an effective amount of a composition containing a Tau phosphopeptide conjugated to an immunogenic carrier.

公开(公告)号：US20250049740A1

公开(公告)日：2025-02-13

申请号：US18923008

申请日：2024-10-22

Applicant: TAO SUN

Inventor： TAO SUN

IPC: A61K31/167 ,  A01K67/027 ,  A61P1/00 ,  A61P25/28 ,  A61P29/00

Abstract: The present disclosure relates to a compound and the use thereof in the preparation of a medicament for treating Alzheimer's disease. The present disclosure provides a method for constructing an animal model of diseases with N-oleoyl-dopamine (OLDA) and the use of the model in drug screening and animal experimental research, wherein the animal model includes at least one of an animal model of neurodegenerative diseases, an animal model of intestinal permeability diseases, and an animal model of inflammatory diseases. The present disclosure is based on the discovery that OLDA has a new use for a neurodegenerative disease, an intestinal permeability disease, and an inflammatory disease, and based on OLDA, compounds that have a therapeutic effect on the above diseases are identified.

公开(公告)号：US20250041350A1

公开(公告)日：2025-02-06

申请号：US18577427

申请日：2023-05-03

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY

Inventor： MI SOOK CHANG ,  SEONG HO KOH ,  EUN JI LEE

IPC: A61K35/30 ,  A61P25/28 ,  C12N5/079

Abstract: A composition for prevention or treatment of vascular dementia includes glia-like cells differentiated from human mesenchymal stem cells (hMSCs). The composition may induce the regeneration of cerebral cells or glia cells or inhibits further damage, such that the composition can be used as a therapeutic agent for preventing or treating vascular dementia.

公开(公告)号：US12215149B2

公开(公告)日：2025-02-04

申请号：US17722624

申请日：2022-04-18

Applicant: Alector LLC

Inventor： Philip Kong ,  Herve Rhinn ,  Tina Schwabe ,  Angie Yee ,  Arnon Rosenthal

IPC: C07K16/18 ,  A61K39/00 ,  A61P25/28 ,  C07K16/28

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20250032521A1

公开(公告)日：2025-01-30

申请号：US18814957

申请日：2024-08-26

Applicant: Sydney David CULLIS-HILL

Inventor： Sydney David CULLIS-HILL

IPC: A61K31/7008 ,  A61P25/28

Abstract: The present invention relates to acetyl glucosamine. In particular, the present invention relates to the use of acetyl glucosamine to improve cognition.